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Non-valvular atrial fibrillation (AF) is the most frequent
cardiac arrhythmia in aging population. It was estimated
that 2.3 million US adults had AF in 2001, extrapolated
to 2.5-fold increase by 2050.1 AF produces turbulence of
blood and endothelial injury in the left atrium (and its
appendage) with consequential arterial thrombo-
embolism. Clinically, the most significant event is the
possibility of ischemic stroke (IS) as well as peripheral
thrombi. Therefore, patients with AF irrespective of
whether it is paroxysmal, persistent or permanent,
require lifelong thromboprophylaxis. Anticoagulation
reduces the risk of IS and other peripheral thrombi
by approximately two-thirds of the baseline risks.
Additionally, it not only decreases the severity of IS but it
also decreases the 30-day mortality following stroke, if it
does occur.
Given that anticoagulant therapy has both risks (principally
bleeding) and benefits (reduced risk of thrombosis),
many scoring systems have been described to estimate
the risks of these outcomes. However, no single system
is universally accepted or highly predictive. Gage et al.
validated various classification schemes using clinical
data of 1,733 patients, and concluded that CHADS2
scoring can predict the risk of IS in patients with AF.2 In
CHADS2, 1 point is assigned each for the presence of
congestive heart failure, hypertension, age 75 years or
older, and diabetes mellitus; and 2 points for the history
of stroke or transient ischemic attack. They reported
that the risk of stroke per 100 patient-years (without
anticoagulation) increased by 1.5-fold for each point
increase in CHADS2. In 2010, CHADS2, was further
refined to CHA2DS2-Vasc by adding additional risk
factors like female gender (1 point) and vascular disease
(1 point for history of myocardial infarction, peripheral
artery disease) and assigning 2 points to age >75 years
instead of one-point in original scheme.3 As anti-
coagulating a patient will increase his bleeding risk;
therefore, hemorrhagic risk assessment is also done.
However, it is not clear that to what extent this scoring
will affect decision-making during anti-coagulation of
patients with AF. Apostolakis et al. compared various
bleeding-risk prediction scores in AF and concluded that
HAS-BLED score can estimate the risk of bleeding,
particularly intracranial bleeding in patients taking anti-
coagulation.4 In HAS-BLED, one point each is assigned
to hypertension, abnormal renal or hepatic function,
stroke, bleeding, labile INR, elderly (>65 years) and
drug or alcohol intake. Accordingly, an AF patient having
a HAS-BLED score of >3 is at increased risk of bleeding.
American College of Chest Physicians (ACCP)
guidelines recommend thrombo-prophylaxis with oral
anticoagulation for patients with AF who are at high risk
of stroke (CHADS2 >2), while those having lower risk
need personalised approach for AF management.5
Similarly, guidelines are given by European Society of
Cardiology, American College of Cardiology Foundation,
and American Heart Association for anti-coagulating
patients with AF.
Traditionally, oral vitamin K antagonist (VKA), e.g.
warfarin, has been used to anti-coagulate patients with
AF. However, this medication requires continuous
laboratory monitoring to achieve a target of 2-3 of
international normalised ratio, and has significant drug-
drug, drug-disease and drug-food interaction. Moreover,
intra-cerebral bleeding is the most dreadful complication
of VKA toxicity. New oral anticoagulants (NOACs)
revolutionise the prophylaxis and treatment of
thrombotic disorders as they are taken in fixed doses, do
not routinely require laboratory monitoring, and do not
have drug-, food-, or disease interactions. Food and
Drug Administration (FDA) authority approved NOACs
for thromboprophylaxis in AF including direct thrombin
inhibitor (dabigatran in 2010) and anti-Xa inhibitors
(rivaroxaban in 2011, apixaban in 2012 and edoxaban in
2015). A meta-analysis, comparing safety and efficacy of
NOACs with warfarin in over 44,000 patients, reported
that NOACs were more efficacious than warfarin in
preventing stroke and systemic embolism, and have
lower risk of intracranial bleeding in patients with AF.6
However, these results have been challenged recently
because of lack of robustness in these clinical trials.7 In
contrast to VKA that acts by inhibiting hepatic synthesis
of vitamin K-dependent clotting factors (II, VII, IX and X),
NOACs function by inhibiting active forms of clotting
factors like IIa (by dabigatran) and Xa (by anti-Xa
inhibitors). Bioavailability of NOACs ranges from 6% for
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dabigatran to 80% for rivaroxaban and apixaban. Their
peak action starts within 1-3 hours (in contrast to 48-72
hours for VKAs) and are dependent on renal clearance
for elimination.
One of the barriers in using NOACs is high prescription
cost when compared with VKA. Conversely, recent
reports from European countries have shown cost
effectiveness of NOACs with improvement in quality-
adjusted life years. Secondly, a dose adjustment is
required for patients with renal failure as NOACs are
mainly dependent on renal function for their clearance.
Thirdly, NOACs till very recently had no antidotes for
bleeding or surgical patients who require immediate
reversal of anticoagulation. Hence, such patients were
managed with supportive care on similar lines as a
patient who is bleeding secondary to VKA toxicity.
Recently, FDA-approved direct reversal agents
(idarucizumab for dabigatran and andexanet alfa for FXa
inhibitors) have been launched that may be useful for
fast reversal of NOACs as compared to previously used
reversal agents.8 Finally, laboratory monitoring of
NOACs is problematic. Though patients receiving
NOACs are not routinely monitored, but laboratory
testing becomes important when such a patient starts
bleeding or requires surgery. Conventional prothrombin
time (PT) and activated partial thromboplastin time
(APTT) provide only qualitative assessment or limited
information for NOACs. Therefore, while normal PT and
APTT exclude the presence of clinically important drug
effect, abnormal tests indicate that anticoagulation effect
of NOACs is present. Thrombin time or diluted thrombin
time for dabigatran and validated anti-Xa assay for
rivaroxaban and apixaban can be used for monitoring.
Besides the limitations discussed above, patients with
AF who were switched from VKA to NOACs reported
more frequent bruising and depression/anxiety.9
In Pakistan, we do not know the true quantum of disease
burden as well as type and frequency of treatment
received. An insight was provided by a report from
Ikramullah et al., who reported anticoagulation in 205
patients with AF at two tertiary care academic institutes.
Of 149 (73%) patients who were candidates of
anticoagulation (according to risk stratification using
CHA2DS2-Vasc), 27.5% received VKA or NOACs while
remaining patients received either dual antiplatelet
agents (35%), single antiplatelet agent (30%) or no
treatment (7%).10
This report does not describe details of NOACs
prescription; however, it provides a glimpse of real life
scenario in indigenous setting. There are patients-at-
large in our communities who do not visit any doctor or
die of IS secondary to AF before any medical help can
be provided. The lack of local data necessitates large
scale prospective studies for evaluating the true
magnitude of AF, frequency of IS, type, compliance, cost
effectiveness, and complications of anticoagulation as
well as quality of life in patients having AF.
REFERENCES
1. Go AS, Hylek EM, Phillips KA. Prevalence of diagnosed atrial
fibrillation in adults: national implications for rhythm
management and stroke prevention: the anti-coagulation and
risk factors in atrial fibrillation (ATRIA) study. JAMA 2001;
285:2370-5.
2. Gage BF, Waterman AD, Shannon W, Boechler M, Rich MW,
Radford MJ. Validation of clinical classification schemes for
predicting stroke: results from the national registry of atrial
fibrillation. JAMA 2001; 285:2864-70.
3. Lip GY, Nieuwlaat R, Pisters R, Lane DA, Crijns HJ. Refining
clinical risk stratification for predicting stroke and thrombo-
embolism in atrial fibrillation using a novel risk factor-based
approach: the euro heart survey on atrial fibrillation. Chest
2010; 137:263-72.
4. Apostolakis S, Lane DA, Guo Y, Buller H, Lip GY. Performance
of the HEMORR(2) HAGES, ATRIA, and HAS-BLED bleeding
risk-prediction scores in patients with atrial fibrillation
undergoing anticoagulation: the AMADEUS (evaluating the
use of SR34006 compared to warfarin or acenocoumarol in
patients with atrial fibrillation) study. J Am Coll Cardiol 2012;
60:861-7.
5. You JJ, Singer DE, Howard PA. Antithrombotic therapy for
atrial fibrillation. Chest 2012; 141:e531S-75S.
6. Miller CS, Grandi SM, Shimony A, Filion KB, Eisenberg MJ.
Meta-analysis of efficacy and safety of new oral anticoagulants
(dabigatran, rivaroxaban, apixaban) versus warfarin in patients
with atrial fibrillation. Am J Cardiol 2012; 110:453-60.
7. Camm AJ, Fox KAA, Peterson E. Challenges in comparing the
non-vitamin K antagonist oral anticoagulants for atrial
fibrillation-related stroke prevention. Europace 2018; 20:1-11.
8. Udayachalerm S, Rattanasiri S, Angkananard T, Attia J,
Sansanayudh N, Thakkinstian A. The reversal of bleeding
caused by new oral anticoagulants (NOACs): A systematic
review and meta-analysis. Clin Appl Thromb Hemost 2018:
1076029618796339.
9. De Caterina R, Bruggenjurgen B, Darius H. Quality of life and
patient satisfaction in patients with atrial fibrillation on stable
vitamin K antagonist treatment or switched to a non-vitamin K
antagonist oral anticoagulant during a 1-year follow-up: A
PREFER in AF registry substudy. Arch Cardiovasc Dis 2018;
111:74-84.
10. Ullah I, Ahmad F, Ahmad S, Hayat Y. Atrial fibrillation and
stroke prevention practices in patients with candidacy for
anticoagulation therapy. J Ayub Med Coll Abbottabad 2015;
27:669-72.
Journal of the College of Physicians and Surgeons Pakistan 2019, Vol. 29 (1): 2-3 3
